You are viewing: Japan Biobanking Market analysis
Part of: Biobanking Market (Global)

The Japan Biobanking Market was valued at $292.8 Million in 2025 and projected to reach to $449.1 Million by 2030, representing a compound annual growth rate of 8.9%. Japan's biobanking market is positioned for sustained growth over the next five years, driven by the country's aging population and increasing prevalence of chronic diseases requiring advanced diagnostic and research capabilities.

Japan Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Biobanking Market Trends and Insights

  • Japan's advanced healthcare infrastructure and aging population are driving demand for biobanking services, including sample collection, storage, and analysis.
  • The country's strong regulatory framework and emphasis on precision medicine are positioning Japan as a key player in the Asia Pacific biobanking sector. Japan's biobanking market benefits from increasing investment in genomic research and personalized medicine initiatives.
  • Japan's pharmaceutical and biotechnology companies are leveraging biobanks to accelerate drug development and clinical trials.
  • The integration of digital technologies and automation in Japan's biobanking facilities is enhancing operational efficiency and data management capabilities. Japan's market growth is supported by collaborations between academic institutions, hospitals, and private biobanking providers.
  • Japan's commitment to advancing regenerative medicine and stem cell research is creating additional opportunities for biobank expansion through 2030..

Key Market Statistics

  • CAGR (2025-2030) 8.9% CAGR
  • Market Size, 2025 ~USD 292.8 Million
  • Forecast, 2030 ~USD 449.1 Million
  • Country Japan

Japan Biobanking Market Overview

Market Valuation :

Japan's biobanking market is valued at USD 292.8 million in 2025, with a projected CAGR of 8.9% through 2030, reaching USD 449.1 million by forecast end.

Aging Population Driver :

Japan's rapidly aging demographic is a primary catalyst for biobanking growth, increasing demand for sample collection, storage, and analysis services for age-related disease research and personalized medicine.

Advanced Healthcare Infrastructure :

Japan's sophisticated healthcare system and technological capabilities provide a robust foundation for biobanking operations, enabling high-quality sample management and regulatory compliance.

Precision Medicine Focus :

Strong emphasis on precision medicine and genomic research in Japan is driving adoption of biobanking services, supported by a stringent regulatory framework that ensures data integrity and ethical standards.

Japan Biobanking Market Dynamics

  • The integration of precision medicine into clinical practice and the government's support for genomic research initiatives are expected to accelerate market expansion.
  • Japan's commitment to maintaining world-class healthcare standards and investing in biotechnology infrastructure will continue to attract both domestic and international biobanking investments, solidifying the country's role as a leader in Asia-Pacific biobanking services..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Japan's biobanking market is valued at USD 292.8 million in 2025 and is expected to reach USD 449.1 million by 2030, representing an 8.9% CAGR.
    • Japan's aging population and advanced healthcare infrastructure are primary drivers of biobanking demand for precision medicine and personalized treatment approaches.
    • Japan's investment in genomic research and regenerative medicine is expanding biobank applications in drug development and clinical research.
    • Japan's regulatory framework and institutional collaborations are strengthening the country's position as a leading biobanking hub in the Asia Pacific region.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Japan Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    JAPAN: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES20.821.623.625.928.631.735.239.210.7
    HOSPITALS & DIAGNOSTIC LABORATORIES12.412.813.915.216.818.520.522.710.2
    PHARMA-BIOTECH COMPANIES & CROS49.351.356.161.968.776.384.994.811.1
    TOTAL82.585.793.6103.1114.1126.5140.6156.610.8

    JAPAN: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS206.1212.5227245.2266.5290.8318.7350.69.1
    CROS60.56265.970.776.382.890.198.58.4
    TOTAL266.6274.5292.8315.9342.8373.6408.8449.18.9

    Target Audience

    • Biobanking Service Providers : Companies offering sample collection, storage, and analysis services need Japan-specific market data to assess market entry opportunities, competitive positioning, and revenue potential in this growing healthcare segment.
    • Pharmaceutical & Biotech Companies : Drug developers and biotech firms require detailed insights into Japan's biobanking infrastructure and precision medicine adoption to optimize clinical trial recruitment and accelerate drug development timelines.
    • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Japan's healthcare sector need comprehensive market analysis, growth projections, and regulatory insights to make informed investment decisions in biobanking ventures.
    • Hospital & Research Institutions : Japanese hospitals and research centers need market intelligence on biobanking best practices, technology trends, and funding opportunities to enhance their research capabilities and patient care services.
    • Government & Policy Makers : Japanese healthcare policymakers and government agencies require market data to inform healthcare infrastructure investments, precision medicine initiatives, and biobanking regulatory frameworks.

    Key Companies in the Japan Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Japan-Specific Market Sizing : Obtain precise valuation data for Japan's biobanking market with verified 2025 baseline (USD 292.8M) and 2030 forecast (USD 449.1M), enabling accurate business planning and investment decisions.
    • Demographic Insights : Understand how Japan's aging population dynamics directly impact biobanking demand, with detailed analysis of age-related disease prevalence and research funding trends specific to the Japanese market.
    • Regulatory Landscape Analysis : Gain comprehensive insights into Japan's stringent biobanking regulations, compliance requirements, and ethical frameworks that differentiate the market and influence operational strategies.
    • Competitive Positioning : Identify key players, market consolidation trends, and competitive dynamics within Japan's biobanking sector to inform partnership and expansion strategies in this high-growth market.
    • Growth Opportunity Assessment : Leverage Japan-specific CAGR data (8.9%) and precision medicine adoption trends to identify high-potential segments, investment opportunities, and revenue streams within the Japanese biobanking ecosystem.

    Frequently asked questions

    What is the current size of Japan's biobanking market?

    Japan's biobanking market is valued at USD 292.8 million in 2025 and is projected to grow to USD 449.1 million by 2030.

    What is the growth rate of Japan's biobanking market?

    Japan's biobanking market is growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2030.

    What factors are driving growth in Japan's biobanking market?

    Japan's biobanking market growth is driven by an aging population, increased investment in genomic research, precision medicine initiatives, and collaborations between academic and private institutions.

    How is Japan's biobanking market segmented?

    Japan's biobanking market includes segments for sample collection and storage, data management, genomic analysis, and biobank services for pharmaceutical and research applications.

    What role does technology play in Japan's biobanking sector?

    Technology integration in Japan's biobanking facilities includes automation, digital data management systems, and advanced analytical tools that enhance operational efficiency and research capabilities.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status